Stockscreener 앱 받기
1.86
2.20%
0.04
전일 마감가:
$1.82
열려 있는:
$1.85
하루 거래량:
12,482
Relative Volume:
0.10
시가총액:
$4.18M
수익:
-
순이익/손실:
$-9.32M
주가수익비율:
-0.1463
EPS:
-12.7107
순현금흐름:
$-7.30M
1주 성능:
+5.68%
1개월 성능:
+19.22%
6개월 성능:
-10.58%
1년 성능:
-43.98%
1일 변동 폭
$1.7288
$1.87
1주일 범위
$1.72
$1.96
52주 변동 폭
$0.952
$6.39
Tharimmune Inc Stock (THAR) Company Profile
명칭
Tharimmune Inc
전화
302-743-2995
주소
1200 ROUTE 22 EAST, BRIDGEWATER
THAR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
1.86 | 4.18M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tharimmune Inc 주식(THAR)의 최신 뉴스
Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors - The Holland Sentinel
EON Resources Inc. Announcement - Worcester Telegram
AINOS (NASDAQ: AIMD) Signs Long-Form Interview and National TV Commercial Agreement with New to The Street - Lubbock Avalanche-Journal
Tharimmune announces key leadership changes to advance pipeline - Investing.com
Navy SEAL Commander Joins Biotech Developing Military Defense Against Weaponized Fentanyl - Stock Titan
Don Kim Resigns as CFO of Tharimmune effective immediatelySEC filing - MarketScreener
Interactive Strength Inc. (Nasdaq:TRNR) Closes Initial $55 Million Investment for Crypto Treasury Strategy and Begins Acquiring $FET - Lohud
Hawley Crescent Catering & Events Wins 2025 Consumer Choice Award for Catering Excellence in Durham Region - Cincinnati Enquirer
Tharimmune announces executive changes and new agreements - Investing.com Australia
Tharimmune announces executive changes and new agreements By Investing.com - Investing.com Nigeria
TharimmuneRandy Milby Resigns As CEO And Board Member - marketscreener.com
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 - IndyStar
Tharimmune Holds Annual Meeting, Elects Directors - TipRanks
Tharimmune (THAR) Appoints Strategic Advisor to Enhance TH104 De - GuruFocus
Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - Jonesboro Sun
FDA Clears Path for Tharimmune's Military Fentanyl Defense Drug as Navy SEAL Commander Joins Advisory Team - Stock Titan
Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Tharimmune, Inc. SEC 10-Q Report - TradingView
Tharimmune appoints new executive chairman By Investing.com - Investing.com India
Tharimmune appoints new executive chairman - Investing.com Australia
Tharimmune IncAppoints Vincent Lopriore As Executive ChairmanSEC Filing - marketscreener.com
Tharimmune (THAR) Reports Promising Phase 1 Results for TH104 Bu - GuruFocus
Tharimmune (THAR) Advances TH104 as Key Medical Countermeasure | - GuruFocus
Tharimmune advances opioid prophylaxis drug TH104 - Investing.com
Tharimmune advances opioid prophylaxis drug TH104 By Investing.com - Investing.com South Africa
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback - Weatherford Democrat
Tharimmune's New Drug Breakthrough: FDA Fast-Tracks Military Protection Against Weaponized Fentanyl - Stock Titan
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences - Chronicle-Tribune
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors - Bluefield Daily Telegraph
Stocks of Tharimmune Inc (THAR) are poised to climb above their peers - Sete News
Breakthrough Drug TH104 Clinical Data Selected for Two Premier Medical Conferences DDW and EASL - Stock Titan
Tharimmune Appoints Clay Kahler And Gary Stetz To Board - citybiz
Tharimmune (THAR) Expands Board with New Appointments | THAR Sto - GuruFocus
Tharimmune expands board with two new directors By Investing.com - Investing.com India
Tharimmune expands board with two new directors - Investing.com
Tharimmune Adds $500M Success Story Entrepreneur and Financial Expert to Board Leadership - Stock Titan
Tharimmune Inc’s latest rating changes from various analysts - knoxdaily.com
Tharimmune Inc (THAR) Stock: Uncovering 52-Week Market Trends - investchronicle.com
These Numbers Show Just How Powerful Tharimmune Inc (NASDAQ: THAR) Stock Is - Stocksregister
Tharimmune expands board, appoints new directors By Investing.com - Investing.com Nigeria
Tharimmune expands board, appoints new directors - Investing.com
FDA Nods to Tharimmune’s Countermeasure for Opioid Threats By Investing.com - Investing.com South Africa
FDA Nods to Tharimmune’s Countermeasure for Opioid Threats - Investing.com Australia
Now Is The Time To Build A Position In Tharimmune Inc (NASDAQ:THAR) - Marketing Sentinel
Observations on the Tharimmune Inc (NASDAQ:THAR) Growth Curve - uspostnews.com
Tharimmune (THAR) Advances TH104 with FDA Feedback on New Drug A - GuruFocus
Tharimmune (THAR) Advances TH104 with FDA Feedback on New Drug Application | THAR Stock News - GuruFocus
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - The Joplin Globe
FDA Clears Path for Tharimmune's Military-Grade Fentanyl Defense Drug: No New Trials Needed - Stock Titan
Tharimmune Inc (THAR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tharimmune Inc 주식 (THAR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Parikh Sanam | Director |
Jun 20 '25 |
Buy |
1.45 |
1,000 |
1,450 |
1,770 |
| Appajosyula Sireesh | Chief Executive Officer |
Jun 20 '25 |
Buy |
1.48 |
61,496 |
90,973 |
64,868 |
| Parikh Sanam | Director |
May 15 '25 |
Buy |
1.30 |
770 |
1,001 |
770 |
| MILBY RANDY | CEO |
Dec 19 '24 |
Buy |
2.12 |
4,600 |
9,752 |
17,534 |
| Appajosyula Sireesh | Chief Operating Officer |
Nov 13 '24 |
Buy |
2.02 |
5,000 |
10,096 |
10,758 |
| MILBY RANDY | CEO |
Oct 08 '24 |
Buy |
2.09 |
2,500 |
5,221 |
12,934 |
| Appajosyula Sireesh | Chief Operating Officer |
Oct 08 '24 |
Buy |
1.93 |
5,000 |
9,650 |
16,364 |
0.68%
0.50%
자본화:
|
볼륨(24시간):